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Background: Human respiratory syncytial virus (hRSV) is a leading cause of severe lower respiratory infection and a
major public health threat worldwide. To date, no vaccine or effective therapeutic agent has been developed. In a
screen for potential therapeutic agents against hRSV, we discovered that an extract of Rosmarinus officinalis exerted
a strong inhibitory effect against hRSV infection. Subsequent studies identified carnosic acid as a bioactive
constituent responsible for anti-hRSV activity. Carnosic acid has been shown to exhibit potent antioxidant and
anti-cancer activities. Anti-RSV activity of carnosic acid was further investigated in this study.
Methods: Effects of extracts from various plants and subfractions from R. officinalis on hRSV replication were
determined by microneutralization assay and plaque assay. Several constituents were isolated from ethyl acetate
fraction of R. officinalis and their anti-RSV activities were assessed by plaque assay as well as reverse-transcription
quantitative PCR to determine the synthesis of viral RNAs.
Results: Among the tested bioactive constituents of R. officinalis, carnosic acid displayed the most potent anti-hRSV
activity and was effective against both A- and B-type viruses. Carnosic acid efficiently suppressed the replication of
hRSV in a concentration-dependent manner. Carnosic acid effectively suppressed viral gene expression without
inducing type-I interferon production or affecting cell viability, suggesting that it may directly affect viral factors. A
time course analysis showed that addition of carnosic acid 8 hours after infection still effectively blocked the
expression of hRSV genes, further suggesting that carnosic acid directly inhibited the replication of hRSV.
Conclusions: The current study demonstrates that carnosic acid, a natural compound that has already been shown
to be safe for human consumption, has anti-viral activity against hRSV, efficiently blocking the replication of this
virus. Carnosic acid inhibited both A- and B- type hRSV, while it did not affect the replication of influenza A virus,
suggesting that its antiviral activity is hRSV-specific. Collectively, this study suggests the need for further evaluation
of carnosic acid as a potential treatment for hRSV.
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Human respiratory syncytial virus (hRSV), a single-
stranded RNA virus of the family Paramyxoviridae, is a
leading cause of lower respiratory tract infection in
infants and children [1]. This is especially true for high-
risk groups, including infants with congenital heart dis-
ease and immunosuppressed patients, where infection
by hRSV causes severe mortality [2]. It has been* Correspondence: innks@khu.ac.kr
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reproduction in any medium, provided the orestimated that acute lower respiratory infection by hRSV
caused approximately 66,000–199,000 deaths of children
under the age of five worldwide in 2005 [3]. Despite the
severity of the global health threat and economic burden
posed by hRSV infection, no effective hRSV-specific
antiviral agents have been developed to date. Ribavirin, a
nucleoside analog, is the only approved drug for severe
hRSV infection, but it is not recommended owing to
several factors, including its toxicity and difficulty of ad-
ministration [4]. Notably, ribavirin has shown limited ef-
ficacy in clinical trials on children with bronchiolitis
caused by hRSV [5-8]. Although immunoprophylaxisd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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MedImmune) confers substantial protection against se-
vere hRSV diseases, no licensed vaccine is currently
available. Thus, there is an urgent need for the develop-
ment of effective and safe vaccines and therapeutics. Pre-
vious studies showed inhibition of hRSV by several natural
compounds, including amentoflavone [9]; anagyrine,
oxymatrine, sophoranol, wogonin, and oroxylin A [10]; 3-
alpha-hydroxy-lup-20(2 9)-ene-23,28-dioic acid and 3-epi-
betulinic acid 3-O-sulfate [11]; and cimicifugin [12].
Extract from Rosmarinus officinalis (Rosemary) has
been known to possess strong antioxidant activity and
widely used for food preservation [13]. In traditional
medicine, R. officinalis has been used to treat various
conditions [14]. In addition, R. officinalis has been used
as a traditional medicine to treat various infectious dis-
eases, and its antimicrobial effect against various bateria
has been proved by several studies [15-17]. Among its
constituents, carnosic acid (CAS #3650-09-7), a
benzenediol abietane diterpene and its degradation
product carnosol are well known antioxidative com-
pounds [18]. In addition to its antioxidant activity,
carnosic acid exerts growth-inhibitory effects on breast
cancer cells [19], ovarian cancer cells [20], and prostate
cancer cells [21] by inducing apoptosis. Carnosic acid
also possesses anti-bacterial, anti-inflammatory and
neuroprotective activities [22-24]. Although carnosic
acid has been shown to inhibit human immunodefi-
ciency virus (HIV) protease activity [25], little is known
about the antiviral actions of carnosic acid.
In this study, we found that carnosic acid from R.
officinalis was capable of inhibiting hRSV infection and
replication, suggesting its potential therapeutic and
prophylactic use against hRSV infection.Figure 1 Antiviral activity of R. Officinalis extract against hRSV. (A) An
A549 cells (5 × 104 cells/well) were infected with hRSV A2 (1000 pfu) and t
Expression of hRSV fusion (F) protein was assessed by microneutralization a
and data represent means ± SD. (B) Viral yield-reduction assay. A549 cells w
hour prior to hRSV infection (0.5 MOI). Viruses were harvested 3 days after
plaques (means ± SD). * p < 0.05 versus vehicle. ** p < 0.01 versus vehicle.Results and discussion
R. Officinalis extract inhibits the replication of hRSV
In order to identify natural antiviral agents against hRSV,
we screened MeOH extracts of a variety of plants
for anti-hRSV activities using a microneutralization
assay. Among tested samples, extracts from Ailanthus
altissima, Cynanchum atratum, and R. officinalis
displayed concentration-dependent inhibition of the ex-
pression of F protein in hRSV-infected cells (Figure 1A).
To confirm the anti-hRSV activities of the extracts, we
determined their effects on the production of hRSV
from infected cells. A549 cells in media containing 20
μg/ml of each extract were infected with hRSV A2 virus
at an MOI (multiplicity of infection) of 0.5 for 3 days,
followed by an analysis of virus production by plaque
assay. As shown in Figure 1B, treatment with R.
officinalis extract reduced virus production by approxi-
mately a 66-fold compared to vehicle treatment, whereas
treatment with A. altissima extract resulted in approxi-
mately a 2.2-fold reduction and C. atratum extract had
no significant effect. These results suggest that some
components of R. officinalis possess anti-hRSV activity.
Thus, R. officinalis extract was used in subsequent
experiments designed to isolate anti-hRSV compound(s).
Isolation of compounds from R. officinalis
n-Hexane-soluble, EtOAc-soluble, BuOH-soluble, and
water-soluble fractions were extracted from the total EtOH
extract of R. officinalis as described in Materials and
Methods. Fractions capable of inhibiting hRSV replication
were identified by testing their effects on hRSV replication
using a microneutralization assay. As depicted in Figure 2A,
the EtOAc-extracted fraction displayed anti-hRSV activity
comparable to that of the total EtOH extract of R.ti-hRSV effects of extracts of A. altissima, C. atratum, and R. officinalis.
reated with different concentrations of total extracts or vehicle (DMSO).
ssay using an anti-F antibody. The assay was performed in duplicate
ere treated with vehicle or 20 μg/ml of the indicated compounds 1
infection and titrated by plaque assay. Data represent number of
Figure 2 Isolation of compounds from R. officinalis. (A) Anti-hRSV effect of the EtOAc fraction of R. officinalis EtOH extract. Anti-hRSV activities
of EtOAc-soluble, hexane-soluble, BuOH-soluble, and total EtOH extracts were assessed by microneutralization assay as described in Figure 1. Data
represent means ± SD. (B) Chemical structures of compounds isolated from the EtOAc fraction, which showed the strongest anti-hRSV activity.
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compounds in the EtOAc faction. To identify the molecule
responsible for the inhibitory activity, we further purified
the EtOAc-soluble extract by column chromatography on
silica gel, eluting with n-hexane−EtOAc−MeOH (7:3:0 ↓
0:1:0 ↓ 0:9:1 ↓ 0:4:1 v/v; final stage, MeOH 100%) to
yield seven fractions (F01−F07). Fraction F02 was
chromatographed over reversed-phase silica gel
(MeOH–H2O gradient from 4:1 to 19:1, v/v) to give
carnosic acid and betulinic acid. Ursolic acid and oleanolic
acid were obtained from fraction F03 by reversed-phase col-
umn chromatography, eluting with MeOH–H2O (19:1, v/v).
Fraction F07 was chromatographed over reversed-phase
silica gel to give rosmarinic acid. Chemical structures of
isolated compounds are shown in Figure 2B.
Identification of carnosic acid as the compound
responsible for anti-hRSV activity
To identify the compound capable of inhibiting hRSV
replication, we assessed the anti-hRSV activities ofisolated compounds by RT-qPCR using primers specific
for SH and NS2 proteins of hRSV. Among tested com-
pounds, carnosic acid exerted the strongest inhibition of
viral RNA synthesis (Figure 3A). It is known that R.
officinalis contains carnosol, which has a chemical struc-
ture very similar to that of carnosic acid. Thus, we com-
pared the inhibitory activity of carnosic acid with that of
carnosol. Interestingly, carnosol did not show any signifi-
cant inhibitory activity against hRSV (Figure 3B). In
addition, catechol failed to suppress hRSV RNA synthesis,
suggesting that the carboxylic acid moiety of carnosic acid
might be crucial for its anti-hRSV activity (Figure 3B).
Effect of carnosic acid on interferon production upon
hRSV infection
Type-I and type-III interferons play crucial role in antiviral
immune responses against hRSV. hRSV antagonize the in-
duction of interferons and their actions to escape from im-
mune surveillance using nonstructural (NS) proteins, NS1
and NS2 [26-29]. Thus, we tested the possibility that
Figure 3 Identification of compounds responsible for anti-hRSV activity. (A) Inhibitory activity of isolated compounds toward viral protein
synthesis. A549 cells were treated with the indicated compounds 1 hour prior to hRSV infection (MOI 0.5). cDNAs were synthesized from total
RNA isolated from cells 24 hours after infection. The relative amount of RNA for hRSV NS2 and SH protein were determined by RT-qPCR. Data
represent means ± SD. ** p < 0.01 versus Mock-treated (Mock). A.U.: Arbitrary unit. (B) Comparison of inhibitory activities of carnosic acid,
catechol, and carnosol. Effects of carnosic acid (carnosic), catechol, and carnosol on the synthesis of hRSV F protein RNA was determined as in
(A). Data represent means ± SD. ** p < 0.01 versus Mock-treated (Mock). A.U.: Arbitrary unit.
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quently suppresses the replication of hRSV. None of the
tested compounds upregulated the production of interferon-
β or interferon-λ during hRSV infection, suggesting that the
inhibitory activity of carnosic acid was not due to the induc-
tion of interferon (Figure 4A, B). In fact, the production of
interferon-β and interferon-λ in carnosic acid-treated cells
was actually much lower than that in vehicle-treated cells
after virus infection, possibly due to the low level of hRSV
infection or replication. Treatment of carnosic acid without
virus infection did not induce interferon- β, while Sendai
virus induced high level of interferon-βmRNA (Figure 4C).
Analysis of cytotoxic activity of carnosic acid
To rule out the possibility that nonspecific cytotoxicity
of carnosic acid could affect hRSV replication, we exam-
ined the cytotoxicity of carnosic acid by MTT assay.Figure 4 Effects of carnosic acid on interferon production. Effects of is
production were analyzed by RT-qPCR using the same samples from Figure
(Mock). A.U.: Arbitrary unit. (C) To determine the effect of isolated compou
with carnosic acid without virus infection. Data represent means ± SD. A.UCarnosic acid did not show any significant cytotoxicity at
the concentrations used for antiviral assays (Figure 5A).
The 50% cytotoxic concentration of carnosic acid was
130.8 μg/ml. Effect of carnosic acid on cell viability was
further examined by trypan blue exclusion assay and
apoptosis analysis. As shown in Figure 5B, cells treated
with 50 μg/ml of carnosic acid for 24 hours did not show
any significant decrease in cell viability. The percentage of
viable cells was slightly lowered from 75% to 67 and 62%
by the treatment of 50 μg/ml and 100 μg/ml of carnosic
acid for 48 hours, respectively. Similarly, the treatment of
carnosic acid (20 μg/ml) for 24 hours did not induce
apoptotic cell death of A549 cells. Annexin V-positive
apoptotic cells were slightly increased from 2.2% to 5.28%
by the treatment of carnosic acid for 48 hours (Figure 5C).
Thus, we concluded that carnosic acid does not induce se-
vere cell cytotoxicity at the concentration lower than 50olated compounds on interferon-β (A) and interferon-λ1 and -λ2 (B)
3. Data represent means ± SD. ** p < 0.01 versus Mock-treated
nds themselves on interferon- β production, A549 cells were treated
.: Arbitrary unit.
Figure 5 Effects of carnosic acid on cell viability. (A) Cell cytotoxicity assay. A549 cells were treated with increased concentration of carnosic
acid for 24 hours and subjected to a MTT assay. Data represent means ± SD. (B) Viable cell count assay. A549 cells were treated with increased
amount of carnosic acid for 24 hours or 48 hours. Cells were detached and mixed with trypan blue cell staining solution. Viable cells and dead
cells were counted under microscope. All the experiments were performed in triplicate and data represent the percentage of viable cells
(means ± SD). N.S.: not significant. * p < 0.01 versus Mock-treated (Mock). (C) Apoptosis assay. Apoptotic cell death of A549 cells incubated with
or without carnosic acid (20 μg/ml) for 24 and 48 hours was analyzed by flow cytometry using Annexin V-FITC and propidium iodide.
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to the non-specific cell cytotoxicity of carnosic acid.
Assessment of the anti-hRSV activity of carnosic acid
In experiments using A549 cells and HEp-2 cells, transcrip-
tion of F, NS2 and SH proteins of hRSVA2 was reduced by
treatment with carnosic acid in a concentration-dependent
manner (Figure 6A, B). Estimated average half-maximal in-
hibitory concentration (IC50) values of carnosic acid for
RNA synthesis of viral proteins (F, NS2, and SH protein) in
A549 cells and HEp-2 cells were 19.58 μM (6.51 μg/ml)
and 20.19 μM (6.71 μg/ml), respectively. Effect of carnosic
acid on the replication of influenza virus A was tested to
examine whether antiviral activity of carnosic acid is hRSV
specific or not. Unlike hRSV, viral RNA synthesis from in-
fluenza A virus infected A549 cells was not inhibited by the
treatment of carnosic acid, indicating that carnosic acid
specifically inhibits hRSV replication (Figure 6C). In
addition, this result support that antiviral activity of
carnosic acid is not due to the nonspecific effect on host
cells. The anti-hRSV activity of carnosic acid was further
confirmed by virus yield-reduction assay. Two days afterinfection, treatment with 20 μg/ml (60 μM) or 50 μg/ml
(150 μM) of carnosic acid reduced virus progeny produc-
tion by 26-fold and 1160-fold, respectively (Figure 6D). No
viruses were detected in cells treated with 50 μg/ml (150
μM) of carnosic acid 4 days after infection (Figure 6D),
confirming the inhibitory activity of carnosic acid against
hRSV. Carnosic acid also significantly inhibited NS2 and G
protein RNA synthesis of a hRSV B-type clinical isolate
(hRSV B/KR), indicating that carnosic acid can suppress
both A- and B-type hRSV (Figure 7A and B).
Inhibition of hRSV replication and infection by carnosic acid
To understand the mechanism of hRSV inhibition by
carnosic acid, we investigated the kinetics of carnosic
acid-mediated inhibition of hRSV RNA synthesis. Pre-
treatment of cells with carnosic acid 3 hours prior to in-
fection inhibited hRSV RNA synthesis by approximately
80%, based on quantitative determination of RNA for F
and NS2 protein. Treatment with carnosic acid 4 hours
after infection inhibited synthesis of RNA for F and NS2
protein to a similar degree (~80%) as pretreatment
(Figure 8A). Post-treatment with carnosic acid 8 and 12
Figure 6 Analysis of the anti-hRSV activity of carnosic acid. A549 cells (A) and HEp-2 cells (B) were treated with different concentrations of
carnosic acid. Cells were infected with hRSV A2 virus (MOI 0.5) for 48 hours, followed by RNA preparation and RT-qPCR. The relative amount of
RNA for hRSV F, NS2 and SH protein were determined by RT-qPCR. Data represent means ± SD. ** p < 0.01 versus Mock-treated (Mock). A.U.:
Arbitrary unit. (C) The effect of carnosic acid on influenza A virus replication was tested in A549 cells in a similar manner. Cells were infected with
influenza A/PR8 virus (MOI 0.01) for 24 hours and the relative amount of RNA for influenza A virus NP and P protein were determined by
RT-qPCR. A.U.: Arbitrary unit. (D) Inhibition of progeny virus production by carnosic acid. A549 cells were treated with the indicated compounds 1
hour prior to hRSV infection (MOI 0.1). Two and four days after infection, progeny viruses were harvested and titrated by plaque assay. All the
experiments were performed in triplicate and data represent number of plaques (means ± SD). N/D.: not detected. *** p < 0.001 versus
Mock-treated (Mock).
Figure 7 Inhibition of both A- and B-type hRSV by carnosic acid. Effects of carnosic acid on the synthesis of viral proteins from hRSV B/KR
virus were analyzed by RT-qPCR. A549 cells were treated with carnosic acid 1 hour prior to infection. Twelve and twenty-four hours after virus
infection, RNA levels of each viral protein were quantified by RT-qPCR using type-specific primers. NS2-specific primers (A) and G protein-specific
primers (B) are used to assay antiviral activity against hRSV B/KR. All the experiments were performed in triplicate and data represent means ± SD.
** p < 0.01 versus Mock-treated (Mock). A.U.: Arbitrary unit.
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Figure 8 Inhibition of hRSV replication and infection by carnosic acid. (A) A549 cells were treated with carnosic acid at various times before
and after virus inoculation. Inhibitory effects were analyzed by measuring the synthesis of RNA for viral F and NS2 proteins. (B) Cells were treated
with carnosic acid for 1 hour. After washing five times with PBS to remove carnosic acid, cells were infected with hRSV A2 for 1 hour as follows:
Car-, cells infected with hRSV without carnosic acid; Car+, cells infected with hRSV inoculum containing carnosic acid, then washed with PBS
before further incubation; Car++, cells infected with hRSV inoculum containing carnosic acid and then further incubated in carnosic
acid-containing media. Forty-eight hours after infection, viral protein synthesis was analyzed by RT-qPCR. All the experiments were performed in
triplicate and data represent means ± SD. * p < 0.05 versus Mock-treated (Mock). ** p < 0.01 versus Mock-treated (Mock). A.U.: Arbitrary unit.
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thesis by about 70% and 50%, respectively (Figure 8A).
Although these results suggest that carnosic acid inhibits
hRSV replication, we also tested whether carnosic acid
affected the initial infection of hRSV. We first treated
A549 cells with 10 μg/ml of carnosic acid for 1 hour.
Cells were then infected with hRSV for 1 hour and, after
extensive washing with PBS, were further incubated with
fresh medium with or without carnosic acid. In accord
with our previous data, hRSV RNA synthesis in cells cul-
tured in medium containing carnosic acid (Car++) was
less than 10% of that in cells treated with vehicle (Car-).
Moreover, treatment with carnosic acid only during the
infection process (Car+) resulted in a 50% reduction of
hRSV RNA synthesis, indicating that carnosic acid may
also inhibit hRSV infection (Figure 8B). Viral RNA syn-
thesis in cells infected with hRSV without carnosic acid
(Car-) was similar to that in cells that had never been
treated with carnosic acid (Con), confirming that the in-
hibition is not due to a change in cell physiology, such
as altered interferon production or receptor expression.
In this study, we have shown that carnosic acid effect-
ively suppresses hRSV replication. Carnosic acid showed
similar suppressive effect against both A- and B-type
hRSV, while it did not inhibit influenza A virus replica-
tion. Since carnosic acid did not induce significant cell
death and interferon production at the used concentra-
tion, it is not likely that the inhibitory effect is due to
the effect on host cells. Failure to suppress influenza A
virus also support that notion. Moreover, carnosol,
which has similar structure and possesses antioxidative
activity, was unable to inhibit hRSV RNA synthesis. It
suggests that the suppressive effect of carnosic acid is
not due to the antioxidative activity of carnosic acid.Although the mechanism by which carnosic acid inhibit
the replication of hRSV is unclear, it is likely that it
affect viral factors such as viral proteins. In our study,
we have shown that the levels of viral RNAs were signifi-
cantly lowered by the treatment of carnosic acid on
infected cells by using primers complementary to F, SH,
NS2 and G proteins. Since carnosic acid is unable to in-
hibit the replication of influenza A virus, which also use
negative sense ssRNA as their genome, it is not likely
carnosic acid inhibits hRSV by directly interacting with
viral RNAs. Given that carnosic acid inhibits hRSV repli-
cation by affecting viral proteins, one possible mechan-
ism is carnosic acid act as an inhibitor of viral RNA
synthesis by affecting viral proteins, which are related to
viral RNA synthesis. For example, carnosic acid may dir-
ectly affect RNA polymerase activity of hRSV L protein
or cofactor P protein to suppress hRSV RNA synthesis.
Targeting M2 protein by carnosic acid also can be a pos-
sible hypothesis, since M2 protein of hRSV has been
known to be important for efficient transcription of viral
mRNAs [30]. Time-of-addition study results suggest that
carnosic acid also affect the initial infection step. Thus,
it can be postulated that carnosic acid may play an add-
itional different role in inhibiting hRSV by interacting
viral surface proteins such as F, G and SH proteins. Fur-
ther investigations such as isolation of resistant mutant
viruses or identification of viral proteins which interact
with carnosic acid will reveal the more specific mechan-
ism of inhibition.
Conclusion
The use of ribavirin for the treatment for hRSV infection
is limited by its toxicity and limited efficacy; thus, there
is an urgent need for the development of new
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demonstrates that carnosic acid, which has been used as
a preservative and antioxidant in food, effectively in-
hibits the replication of hRSV. Carnosic acid not only re-
duced viral RNA synthesis, it also inhibited the initial
infection of hRSV. Consequently, hRSV progeny virus
production was greatly reduced by carnosic acid treat-
ment. Since treatment with carnosic acid both pre- and
post-exposure suppressed the replication of hRSV, this
compound might be a potential prophylactic and thera-
peutic agent against hRSV infection.Material and methods
Cells and viruses
The human larynx carcinoma cell line HEp-2 (CCL-23)
and human adenocarcinoma alveolar basal epithelial cell
line A549 were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS) and penicillin/streptomycin (100 U/mL).
hRSV A2 and hRSV KR/B (subgroup B) were described
elsewhere [31]. Viruses were propagated by infecting
HEp-2 cell monolayers with a previously prepared small-
scale isolate stock at a multiplicity of infection (MOI) of
0.01. Viruses were harvested when cytopathic effects
were greater than 60% and were titrated by plaque assay
as described previously [32]. Influenza A/Puerto Rico/8/
1934 virus was propagated in specific pathogen-free em-
bryonated eggs as described previously [33].Plant materials
The rosemary plant (Rosmarinus officinalis L.) and other
plants used in this study were purchased from a local
market at Seoul. A voucher specimen (No. 2012-
ROOF01) has been deposited in the Laboratory of Nat-
ural Product Medicine, College of Pharmacy, Kyung Hee
University.Screening of plant extracts for anti-hRSV activity by
microneutralization assay
Plant extracts were initially screened using microneutralization
assays, as described previously [34]. Briefly, methanol (MeOH)
extracts of each plant were dissolved in DMSO and serially di-
luted with Phosphate buffered saline (PBS). MeOH extracts
(20 μg/ml) of each plant were added to HEp-2 cells (5 × 104
cells/well) together with 1000 plaque-forming units (pfu) of
hRSV A2 virus. Final concentration of DMSO was 2% in all
samples. Three days after infection, cells were fixed with
3.7% formaldehyde. After blocking with 5% skim milk, the
expression of hRSV fusion (F) protein was assessed by
enzyme-linked immune sorbent assay (ELISA) using mouse
anti-F monoclonal antibody (Sino Biological) and horserad-
ish peroxidase (HRP)-conjugated anti-mouse IgG.Extraction and isolation of compounds
Air-dried, powdered aerial parts of R. officinalis (12.5 g)
were extracted three times with 70% ethanol (EtOH) by
maceration. The extracts were combined and concentrated
in vacuo at 40°C to give a 70% EtOH extract (3.11 g). The
extract was suspended in H2O (100 mL) and successively
extracted with n-hexane (3 × 100 mL), ethyl acetate
(EtOAc; 3 × 100 mL), and butanol (BuOH; 3 × 100 mL) to
give n-hexane-soluble (719.7 mg), EtOAc-soluble
(950.2 mg), BuOH-soluble (460.6 mg), and water-
soluble extracts (966.5 mg), respectively. Based on prelim-
inary biological test results, the EtOAc-soluble extract
(940 mg) was subjected to column chromatography on sil-
ica gel to obtain pure compounds. The purities (>95%)
and structures of the obtained compounds were deter-
mined by high-performance liquid chromatography
(HPLC) and nuclear magnetic resonance (NMR) spectros-
copy. The structures of the isolates were identified based
on comparisons of physical and spectroscopic data with
published values.
RNA isolation and reverse-transcription quantitative
real-time polymerase chain reaction (RT-qPCR)
Expression of viral genes was analyzed by RT-qPCR
using CFX-9000 (Bio-Rad) real-time PCR. Total RNA
was extracted from mock-infected or hRSV-infected cells
using an RNeasy RNA extraction kit (Qiagen), according
to manufacturer’s instructions. cDNA was synthesized
from 1 μg of total RNA using Superscript III reverse
transcriptase (Invitrogen) with oligo20(dT) primers. Two
microliters of synthesized cDNA was used as a template
for quantitative PCR. Sequences of primers used for this
study are listed in Table 1.
Effect of carnosic acid on interferon production upon
hRSV infection
The levels of interferon mRNAs were determined by
RT-qPCR. A549 cells were treated with 20 μg/ml of des-
ignated compound one hour prior to hRSV infection.
Cells were then incubated for additional 6 hours,
followed by RNA isolation and RT-qPCR. To analyze the
effect of compounds on interferon production without
viruses, cells were incubated with vehicle or designated
compounds (20 μg/ml) for 6 hours without virus infec-
tion. Primers complementary to interferon-β, λ1 and λ2
(Table 1) were used to analyze mRNA levels. mRNA
levels were normalized to β-actin mRNA levels.
Effect of carnosic acid on viral RNA synthesis
A549 cells were treated with different concentrations of
designated compound one hour prior to hRSV infection.
Cells were then infected with hRSV A2 (MOI 0.5) for an
hour. After washing to remove unbound viruses, cells
were further incubated for 48 hours in media containing
Table 1 List of primers used for RT-qPCR in this study
Target RNA Sense (5′-3′) Anti-sense
hRSV A2 F CCACAATCCTCGCTGCAGTC GGCTCCTAGAGATGTGATAACGG
hRSV A2 NS2 ATTGGCATTAAGCCTACAAAGCA CTTGACTTTGCTAAGAGCCATCT
hRSV A2 SH AATTGGAAGCACACAGCTAC TTGCATTTGCCCCAATGTT
hRSV B G ATGATTGCAATACTAAA ACACTGGTATACCAACC
Influenza A NP TGTGTATGGACCTGCCGTAGC CCATCCACACCAGTTGACTCTTG
Influenza A M2/M1 CTTCTAACCGAGGTCGAAACGTA GGTGACAGGATTGGTCTTGTCTTTA
Interferon-β GAACTTTGACATCCCTGAGGAGATT TGCGGCGTCCTCCTTCT
Interferon-λ1 (IL-29) GGACGCCTTGGAAGAGTCAC AGCTGGGAGAGGATGTGGT
Interferon-λ2 (IL-28) AGGGCCAAAGATGCCTTAGA TCCAGAACCTTCAGCGTCAG
β-actin TGCCGCATCCTCTTCCTC CGCCTTCACCGTTCCAGT
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were isolated and used for RT-qPCR. The replication of
hRSV A2 virus was analyzed using primers complementary
to F protein, SH protein and non-structural protein 1
(NS1). To determine the replication of hRSV B virus,
primers complementary to NS2 and G protein of hRSV B
type were used for quantitative PCR. The replication of in-
fluenza A virus was analyzed using primers complementary
to NP protein and M2/M1 protein. Viral RNA levels were
normalized to β-actin mRNA levels. Sequences of primers
used are listed in Table 1.
Cytotoxicity assay
Cell viability was determined by a MTT (3-(4,5)-
dimenthylthiahiazo(−z-y1)-di-phenytetrazoliumromide) cell
viability assay. A549 cells in a 96-well plate were cultured
in DMEM containing increasing concentrations of carnosic
acid for 48 h. Next, the culture medium was replaced with
fresh medium containing 20 μl of MTT (5 mg/ml) for 4 h.
After that the MTT containing medium was aspirated and
200 μl of DMSO was added to lyse the cells and solubilize
the water insoluble formazone. Absorbance of the lysates
was determined on a microplate reader at 570 nm.Apoptosis assay
Carnosic acid-induced apoptosis was determined by
annexin V and PI double labeling. Cells treated with or
without carnosic acid for 24 or 48 hours were washed
with PBS, and stained with 5 μl of FITC-conjugated
annexin V and 5 μl of PI (50 μg/ml) in 100 μl binding
buffer (10 mM HEPES at pH 7.4, 140 mM NaCl, and 2.5
mM CaCl2). The fluorescence of annexin V and PI were
monitored by FC500 fluorescence-activated cell sorting
(FACS) cater-plus flow cytometry (Beckman Coulter,
CA, USA) at an excitation wavelength of 488 nm and
emission wavelengths of 525 and 625 nm, respectively.
Five thousand events were collected per sample.Virus yield-reduction assay
A549 cells were treated with designated extracts (20 μg/ml)
1 hour prior to hRSV inoculation. hRSV (MOI 0.5) was
then added and cells were incubated for 1 hour to permit
viral internalization. Free virus particles were removed by
washing three times with phosphate-buffered saline (PBS),
and infected cells were further incubated in medium
containing 2% FBS and vehicle (DMSO) or 20 μg/ml of des-
ignated extracts. Viruses were harvested 3 days after infection
and subsequently titrated by plaque assay. To determine the
effect of carnosic acid, carnosic acid (20 μg/ml) was added to
cells instead of extracts. Viruses were harvested 2 or 4 days
after infection and subjected to plaque assay. Viral titer was
expressed as pfu/mL.
Time-of-addition study
A549 cells were seeded and incubated overnight. Cells
were treated with carnosic acid (10 μg/ml) at different
time points before and after viral inoculation (MOI 0.5).
Total RNA was prepared from cells 48 hours after viral
inoculation, followed by RT-qPCR using primers specific
for F and NS2 proteins. The effect of carnosic acid on
the initial infection by hRSV was examined by treating
cells with carnosic acid 1 hour prior to inoculation with
virus. After inoculation, cells were incubated for 1 hour
to allow viral internalization. Free virus and carnosic
acid were removed by extensive washing with PBS. As a
control, cells were treated with carnosic acid for an hour
and washed before viral inoculation to exclude the possi-
bility that carnosic acid altered viral infection or replica-
tion by affecting cell physiology. Total RNA was
prepared from cells 48 hours after viral inoculation and
subjected to RT-qPCR using primers specific for F and
NS2 proteins, as described above.
Statistical analysis
Microneutralization assays and RT-qPCR assays were re-
peated at least three times. Values were expressed as
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http://www.virologyj.com/content/10/1/303means and standard deviation from triplicate samples of
a representative result. Statistical comparisons between
the control and treated groups were analyzed using the
Student’s t-test. The level of statistical significance was
set at either P<0.05 (*), 0.01 (**) or 0.001(***).
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